Spero is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company’s pipeline of anti-infective agents is one of the most unique in the industry – focused on Gram-negative bacterial infections and non-tuberculous mycobacterial infections. Their most advanced product candidate, SPR994, is anticipated to be the first oral carbapenem antibiotic for use in adults to treat multi-drug resistant (MDR) Gram-negative infections. Spero is also pioneering an entirely new therapeutic platform called the Potentiator designed to treat MDR Gram-negative infections in the hospital setting. NASDAQ: SPRO